Explore our recent stories to see what drives us
Grünenthal hormone production site in Santiago de Chile awarded key Brazilian government certification
�This certification will empower us to provide innovative products to women across Latin America.�
Grünenthal has been active in Chile since 1979 and opened its modern hormone facility in 2017. The production site covers 1,150 square metres and acts as Grünenthal’s centre of excellence for producing hormones, women’s health products and contraceptives including pills and gels. The certification from ANVISA now opens up opportunities to supply these products in Brazil, which accounts for almost 50 percent of the pharmaceutical market in Latin America. The certification also provides a boost for Grünenthal’s strong Contract Manufacturing Business in this area of the world, further strengthening our position as the partner of choice for companies across this growing and dynamic region.
This certification from ANVISA is the latest step forward in Grünenthal’s strategic approach to targeting growth opportunities in Latin America. It reflects our strong commitment to outstanding quality, excellent facilities, smooth processes and solid documentation. Moving forward, Grünenthal aims to use this achievement as an opportunity to provide women in Latin America with access to innovative pharmaceutical products – and contribute to enhancing the health and wellbeing of people in this region.
Find out more about our Contract Manufacturing Services: grunenthal-pro.com